Guselkumab was compared to placebo for the treatment of ulce…
Guselkumab was compared to placebo for the treatment of ulcerative colitis in a randomized double-masked controlled trial. At the end of the trial, participants who received guselkumab were 15% more likely to be in remission from their ulcerative colitis (p=0.003). What type of statistical error is the study at risk for?
Read Details